Journal: Pharmaceutics

Article Title: Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs

doi: 10.3390/pharmaceutics11120658

Figure Lengend Snippet: NPs characterization and process yield. Data represent mean ± SD ( n = 3).

Article Snippet: PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in scanning transmission electron microscopy (STEM) mode (Zeiss, Germany).

Techniques:

Journal: Pharmaceutics

Article Title: Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs

doi: 10.3390/pharmaceutics11120658

Figure Lengend Snippet: Graphics showing the diameter, measured by dynamic light scattering (DLS), after incubation of ( A ) pegylated or ( B ) not pegylated poly(lactic- co -glycolic acid)-nanoparticles (PLGA-NPs) in artificial fluids mimicking the saliva (green lines), the gastric juice (blue lines), or proximal intestinal fluid (yellow line). For all conditions, the measurements were carried out at 1, 2, 4, 6, 24 h from the starting point.

Article Snippet: PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in scanning transmission electron microscopy (STEM) mode (Zeiss, Germany).

Techniques: Incubation

Journal: Pharmaceutics

Article Title: Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs

doi: 10.3390/pharmaceutics11120658

Figure Lengend Snippet: Graphics showing ( A ) the amount of RhB released from PLGA-PEG-RhB-NPs after 24 h incubation in artificial fluids mimicking the saliva, the gastric juice, or proximal intestinal fluid (mean ± SD; n = 5); ( B ) emission spectra of poly(lactic- co -glycolic acid)-polyethylene glycol-RhB-nanoparticles (PLGA-PEG-RhB-NPs) incubated in different media.

Article Snippet: PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in scanning transmission electron microscopy (STEM) mode (Zeiss, Germany).

Techniques: Incubation

Journal: Pharmaceutics

Article Title: Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs

doi: 10.3390/pharmaceutics11120658

Figure Lengend Snippet: Comparison of the paclitaxel (PTX) distribution in ( A ) stomach, ( B ) duodenum, ( C ) colon, ( D ) plasma, and ( E ) liver of mice after administration of a single treatment of PTX or PTX-PLGA-PEG-RhB-NPs (20 mg/kg p.o.). The bars are the mean value ± SD ( n = 4).

Article Snippet: PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in scanning transmission electron microscopy (STEM) mode (Zeiss, Germany).

Techniques:

Journal: Pharmaceutics

Article Title: Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs

doi: 10.3390/pharmaceutics11120658

Figure Lengend Snippet: Signal distribution in the gastrointestinal (GI) tract of mice treated with RhB or PLGA-PEG-RhB-NPs. ( A ) Representative ex vivo scanning of the excised organs after washing with saline solutions to remove debris of feces. Animals were sacrificed at 1, 4, and 24 h after the treatment with the same dose of RhB. In the left column, a vehicle-treated mouse was shown to demonstrate the lack of the auto fluorescent component in this analysis. The interval of fluorescence signal intensity associated with the scale of colors is reported on the right. Five animals for each experimental group were used. ( B ) The quantification of the signal associated with the treatment was performed, dividing each sample into three tracts, as shown in the panel. The bars are the value of signal normalized to 100, considering the mean value measured in the stomach of mice treated with RhB alone and sacrificed 1 h after the oral administration. The bars are the mean value ± SD ( n = 5). The Student’s t -test was used to compare the levels between the two groups for each time point. *** p < 0.0001.

Article Snippet: PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in scanning transmission electron microscopy (STEM) mode (Zeiss, Germany).

Techniques: Ex Vivo, Fluorescence

Journal: Pharmaceutics

Article Title: Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs

doi: 10.3390/pharmaceutics11120658

Figure Lengend Snippet: Representative images showing the distribution of RhB in ( A ) stomach and ( B ) duodenum of mice treated with either PLGA-PEG-RhB-NPs or RhB alone. ( A ) In the upper panels, the localization of signal (red) in gastric sections (blue) is shown 1, 4, and 24 h after the oral administration of PLGA-PEG-RhB-NPs. The same procedure has been used to track the presence of the dye in mice receiving the same amount of RhB (lower panels). Scale bar 100 µm. ( B ) Representative images of the duodenum are shown of PLGA-PEG-RhB-NPsand RhB-treated mice in upper and lower panels, respectively. Scale bar 200 µm. The thicker and more intense blue staining in the periphery of the sections represents the basal layer of the duodenum where the exchanges of tissue/blood occur. The red signal is more concentrated to the center, likely corresponding to the lumen close to the apical side of the villi. A higher magnified picture from a mouse sacrificed 1 h after the ingestion of NPs confirms the weak interaction between NPs and villi. In the duodenum of RhB-treated mice, a deep overlapping between the villi and the RhB was observed at both 1 and 24 h after treatment. A higher magnified image confirms the penetration of the dye into the external side of the villi. Scale bar 50 µm.

Article Snippet: PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in scanning transmission electron microscopy (STEM) mode (Zeiss, Germany).

Techniques: Staining

Journal: Pharmaceutics

Article Title: Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs

doi: 10.3390/pharmaceutics11120658

Figure Lengend Snippet: Signal measurement in ( A ) the plasma and ( B ) the liver of mice orally treated with RhB (blue bars) or PLGA-PEG-RhB-NPs (red bars). Animals were sacrificed at 1, 4, and 24 h after the treatment with the same dose of RhB. Five animals for each experimental group were used. In both graphics, quantification of the signal was normalized to the RhB level at 1 h and expressed as 100. The bars are the mean value ± SD ( n = 5). The Student’s t -test was used to compare the levels between the two groups for each time point. *** p < 0.0001. ( C ) Representative images of the signal related to the dye in a section of liver from mice treated with PLGA-PEG-RhB-NPs (upper panel) or RhB alone (lower panel), both sacrificed 1 h after the treatment. Scale bar 50 µm.

Article Snippet: PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in scanning transmission electron microscopy (STEM) mode (Zeiss, Germany).

Techniques:

Journal: Pharmaceutics

Article Title: Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs

doi: 10.3390/pharmaceutics11120658

Figure Lengend Snippet: Longitudinal study to evaluate PLGA-PEG-RhB-NPs internalization in CaCo 2 cells. ( A ) Low magnified pictures showing the progressive penetration of NPs in cells. Representative images have been selected from non-treated cells (NT, left panel). For each image, the nuclei were stained with Hoechst 33258 (blue), whereas high excitation with the laser at the wavelength of 488 nm will allow unveiling the border of the cells by exploiting their auto fluorescent profile (green). Starting from the 1st hour, it is possible to see orange spots obtained by the merge between the red signal referred to the RhB and the green background. These spots became more evident 4 and 24 h after incubation. Scale bar 70 µm. ( B ) Quantification of the percentage of the area (pixels) occupied by NPs for every single cell at the different time-points. Data are expressed as mean value ± SD, n = 10. ( C ) Quantification of the viability of the cells of CaCo 2 after exposure to RhB (orange line), PLGA-PEG-RhB-NPs (yellow line), and Benserazide as inner control (purple line) measured by RealTime-Glo™ MT Cell Viability Assay (Promega kit) 4 and 24 h after incubation The values obtained from non-treated cells were normalized to 100 for each time point. Values are expressed as mean ± SD ( n = 6). The Student’s t -test was used to compare the levels among the two groups for each time point. *** p < 0.0001 compared to NT. ( D ) Higher magnification pictures showing the same field of view achieved 24 h after PLGA-PEG-RhB-NPs incubation. In the left panel, the cell nucleus, in the middle panel, the red spots associated with NPs, and in the right panel, the merge between the three channels. The dotted line is the border of the cell. Scale bar 15 µm.

Article Snippet: PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in scanning transmission electron microscopy (STEM) mode (Zeiss, Germany).

Techniques: Staining, Incubation, Viability Assay

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: PLGA solution parameters (concentration and surfactant screening trails) a

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Concentration Assay, Solvent

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: Hansen solubility graph for PLGA using HSPiP 5th edition 5.3.04 package, δ d , δ h , δ p denote dispersion, polar, and hydrogen components, respectively.

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Solubility, Dispersion

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: Comparison of Hansen solubility parameters of the solvents for dissolving PLGA, δ d , δ p , δ h , δ t denote Hansen dispersion, polar, hydrogen and total solubility parameters, δ v , R a are Bagley's component and solubility parameter distance

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Comparison, Solubility, Dispersion, Solvent

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: Bageley solubility graph of PLGA.

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Solubility

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: SEM images of the electrospun PLGA fibres produced from different solvent systems including (a) 8 w/w% THF-DMF (7-3), (b) 10 w/w% THF-DMF (7-3), (c) 12 w/w% THF-DMF (7-3), (d) 14 w/w% THF-DMF (7-3), (e) 14 w/w% THF-DMF (1-1), (f) 10 w/w% DCM-DMF (7-3), (g) 10 w/w% DCM-DMF (1-1), (h) 12 w/w% DCM-DMF (1-1), (i) 10 w/w% HFIP; scale bar: 10 μm.

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Produced, Solvent

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: SEM images and corresponding fibre diameter and pore size distribution graphs of PLGA scaffolds produced from differently concentrated solutions from HFIP including (a) 6 w/w%, (b) 8 w/w%, (c) 10 w/w%, (d) 12 w/w%; scale bar: 10 μm.

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Pore Size, Produced

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: Effect of solution concentration on (a) average fibre diameter and (b) pore size of PLGA fibres from HFIP solvent system; (*** P < 0.001).

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Concentration Assay, Pore Size, Solvent

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: Effect of solution concentration on (a) Young's modulus, (b) UTS, and (c) strain at break of PLGA scaffolds produced from differently concentrated solutions (HFIP system); (* P < 0.05, ** P < 0.001, *** P < 0.001, N = 5).

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Concentration Assay, Produced

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: Mechanical properties of the PLGA scaffolds developed from different solution concentrations

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques:

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: SEM images of PLGA scaffolds produced from different solvent systems and their corresponding fibre diameter and pore size; (a) 14 w/w% THF-DMF (1-1), (b) 12 w/w% DCM-DMF (1-1), (c) 6 w/w% HFIP; scale bar: 10 μm.

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Produced, Solvent, Pore Size

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: Mechanical properties of the PLGA electrospun scaffolds with comparable morphology using different solvents

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques:

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: XRD profiles of PLGA fibrous scaffolds made from solvent systems including DCM-DMF (1-1, v/v), THF-DMF DCM-DMF (1-1, v/v), and HFIP.

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Solvent

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: The porosity of electrospun PLGA scaffolds prepared from various solvent systems; (* P < 0.05, ** P < 0.001, *** P < 0.001, N = 5).

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Solvent

Journal: RSC Advances

Article Title: Optimizing solvent systems for electrospun PLGA scaffolds: effects on microstructure and mechanical properties for biomedical applications

doi: 10.1039/d4ra07881k

Figure Lengend Snippet: Degradation profiles of electrospun PLGA scaffolds prepared from various solvent systems over a period of 4 weeks.

Article Snippet: PLGA (50-50), M w of 65 000 Da, was purchased from Ashland Specialties Ireland Ltd.

Techniques: Solvent

Journal: Eye

Article Title: Advances in ocular drug delivery systems

doi: 10.1038/s41433-020-0809-0

Figure Lengend Snippet: Aflibercept loaded PLGA microspheres are fabricated using Kang-Mieler modified double-emulsion, solvent evaporation technique. A poly(N-isopropylacrylamide) (PNIPAAm)-based thermoresponsive hydrogel precursors are mixed with poly(ethylene glycol)-co-(l-lactic acid) diacrylate (PEG-PLLA-DA) copolymer. The composite DDS is produced by suspending microspheres in hydrogel precursors and polymerisation is initiated by introducing ammonium persulfate (APS) and N,N,N′N′-tetramethylethylenediamine (TEMED).

Article Snippet: Graybug Vision, Inc (Redwood City, CA, USA) has developed injectable PLGA microparticles for applications involving both the posterior and anterior segments.

Techniques: Modification, Double Emulsion, Solvent, Evaporation, Produced

Journal: Eye

Article Title: Advances in ocular drug delivery systems

doi: 10.1038/s41433-020-0809-0

Figure Lengend Snippet: Ocular drug delivery systems in clinical trials or in development.

Article Snippet: Graybug Vision, Inc (Redwood City, CA, USA) has developed injectable PLGA microparticles for applications involving both the posterior and anterior segments.

Techniques: Clinical Proteomics, Injection, In Situ